Molecular Partners AG - ESG Rating & Company Profile powered by AI
Alternative companies in the scoring peer group for Molecular Partners AG are displayed below. The page is a free Sustainability report for Molecular Partners AG. This report of Molecular Partners AG incorporates intelligence from across the internet as well as from available disclosures by Molecular Partners AG.
Molecular Partners AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.6; made up of an environmental score of 0.0, social score of 3.2 and governance score of 1.6.
1.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1682 | Viracta Therapeutics Inc | 1.7 | Low |
| 1682 | Werewolf Therapeutics Inc | 1.7 | Low |
| 1715 | Molecular Partners AG | 1.6 | Low |
| 1715 | CareDx Inc | 1.6 | Low |
| 1715 | Catalyst Biosciences Inc | 1.6 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Molecular Partners AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Molecular Partners AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Molecular Partners AG report the average age of the workforce?
Sign up for free to unlockDoes Molecular Partners AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Molecular Partners AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Molecular Partners AG disclose cybersecurity risks?
Sign up for free to unlockDoes Molecular Partners AG offer flexible work?
Sign up for free to unlockDoes Molecular Partners AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Molecular Partners AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Molecular Partners AG conduct supply chain audits?
Sign up for free to unlockDoes Molecular Partners AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Molecular Partners AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Molecular Partners AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Molecular Partners AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Molecular Partners AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Molecular Partners AG disclose water use targets?
Sign up for free to unlockDoes Molecular Partners AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Molecular Partners AG have a product recall in the last two years?
Sign up for free to unlockDoes Molecular Partners AG disclose incidents of discrimination?
Sign up for free to unlockDoes Molecular Partners AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Molecular Partners AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Molecular Partners AG disclose parental leave metrics?
Sign up for free to unlockDoes Molecular Partners AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Molecular Partners AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Molecular Partners AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Molecular Partners AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Molecular Partners AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Molecular Partners AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Molecular Partners AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Molecular Partners AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Molecular Partners AG disclose its waste policy?
Sign up for free to unlockDoes Molecular Partners AG report according to TCFD requirements?
Sign up for free to unlockDoes Molecular Partners AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Molecular Partners AG disclose energy use targets?
Sign up for free to unlockDoes Molecular Partners AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Molecular Partners AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Molecular Partners AG
These potential risks are based on the size, segment and geographies of the company.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.